Applications published 28 January 2009

Pharmaceutical compsn having reduced abuse potential
Odidi, Isa; Odidi, Amina 2018150*

Parenteral formulation comprising proton pump inhibitor sterilized in its final container by ionising radiation
AstraZeneca 2018151*

Pre-mixed, ready to use pharmaceutical compsns
EKR Therapeutic; Baxter International; Baxter Healthcare 2018152*

• Liquid oral compsns
Rosemount Pharmaceuticals 2018153*

• Hydrogel suspension and manufacturing process thereof
Otsuka Pharmaceutical 2018154*

• Method for extemporaneous and reversible concentration of liposomes
Centre National de la Recherche Scientifique 2018155*

• Compsns and methods for treating B-cell malignancies
Chimeros 2018156*

• Controlled release formulation comprising anti-epileptic drugs
Astron Research 2018157*

• New form of administration of racecadotril
Bioproject 2018158*

• Colonic drug delivery formulation
School of Pharmacy, University of London 2018159*

• Modified release formulations containing drug-ion exchange resin complexes
Tris Pharma 2018160*

• A pressure-sensitive adhesive compsn comprising cross-linked polyalkylene oxide and water absorbent hydrophobic agents
Coloplast A/S 2018161*

• Methods for the delivery of a beta2 agonist to induce bronchodilation and formulations for use in the same
Tika Laekemedel 2018162*

• Imaging agents and methods
Board of Regents, The University of Texas System 2018163*

• Use of combination preparations comprising antifungal agents
PharmaCon Forschung und Beratung 2018164*

• FGF-receptor agonist dimeric compounds
Sanofi-Aventis 2018165*

• Terephthalamate compounds and compsns, and their use as HIV integrase inhibitors
IRM LLC 2018166*

• Compsns and methods for FGF receptor kinases inhibitors
IRM LLC 2018167*

• Compsns and methods for enhancing mineral levels in animals with reduced environmental impact
Albion International 2018168*

• Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
Teichmann, Alexander Tobias 2018169*

• Medication against breast cancer and related diseases
Teichmann, Alexander Tobias 2018170*

• Delivery of active agents using a chocolate vehicle
Delavau 2018172*

• Magnetorheological fluids and therapeutic uses thereof
Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada 2018173*

• Compsns and methods for producing fermentation products and residuals
Ambrozea 2018174*

• Depolymerisation extraction of compounds from birch bark
Regents of the University of Minnesota 2018175*

• Kiwi extract
Omnica 2018176*

• TTO-based wide spectrum therapeutics, disinfectants and anaesthetics for use in aquaculture
Biomor Israel 2018177*

• Administration of agonist-antagonist in opioid-dependent patients
Voronkov, Michael; Nezhinsky, Efim; Isakulyan, Levon; Ocheret, Daria 2018178*

• Use of antagonists of CXCL13 or CXCR5 for treating wounds or fibrotic diseases
Renovo 2018179*

• Use of thymosin alpha-1 for the treatment of immunological diseases
Sigma-Tau Industrie Farmaceutiche Riunite 2018180*

• Methods of vaccinating subjects receiving immune modulating therapy
Bristol-Myers Squibb 2018181*

• Immunogenic compsns
The Walter and Eliza Hall Institute of Medical Research 2018182*

• Lyophilised therapeutic peptibody formulations
Amgen 2018183*

• Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
The Ludwig Institut for Cancer Research 2018184*

• Use of MAS-G-protein-coupled receptor agonists in the treatment of the metabolic syndrome, its components and its complications
Universidade Federal de Minas Gerais 2018185*

• Nanoparticle and polymer formulations for thyroid hormone analogues, antagonists and formulations thereof
Ordway Research Institute; Charitable Leadership Foundation; Albany College of Pharmacy 2018186*

• Multipurpose adiabatic potable water production apparatus and methods
Island Sky 2018187*

• Real-time detection of influenza virus
Theranos 2018188*